GSK has reaffirmed its commitment to the GAVI Alliance by providing vaccinations to children in developing countries.
240 million doses of Synflorix will be provided by GSK at a small fraction of the price the drug is usually sold for in developed countries. The doses will be given over the next ten years and are set to benefit 80 million children by protecting them from pneumococcal diseases such as meningitis and pneumonia.
GSK had already provided 480 million doses of Synflorix at a heavily discounted price to a number of the poorest countries in the world. The pharmaceutical company also provides the GAVI Alliance with many other drugs, including ones capable of protecting against the rotavirus, cervical cancer, hepatitis B and diphtheria, amongst others. Over 300 million children are to be expected to be protected by 2024 thanks to GSK’s commitment.